Gene Knockout Feasibility Self-Assessment: Ten Constraints

Ask a lab why a knockout project took nine months instead of eight weeks and the answer is rarely about the gene. It is one of four things: the cell type could not be cloned, delivery never worked reliably, the gene turned out to be essential, or nobody had built an assay that could see the phenotype.

Each of those is knowable in advance. Each is cheap to check. Together they determine whether a project is a two-month build or an eighteen-month argument.

This page is the written version of our feasibility self-assessment: the ten questions, how they are weighted, what the score means, and what to do with the result if it comes back low. The interactive version scores your answers automatically; this document explains the logic behind it.

The first four are weighted most heavily in the assessment because they can end a project. The last two change the plan rather than the possibility.

Each answer is scored 0–3 and multiplied by its weight; the total is normalized to 100.

The middle tier is where most real projects land, and where the assessment is most useful: it names the specific constraint rather than pronouncing a verdict.

1. Delivery never validated. The fix is a pilot with a control guide and a measurable edit, in the actual cell type, before any project planning. A week of work.

2. No protein-level validation. Amplicon sequencing plus a protein blot is the standard; anything less cannot support a null claim because in-frame indels and escape isoforms leave functional protein.

3. Assay not validated against a known effect. A positive-control perturbation showing a large, expected change is what makes a null interpretable.

4. Essentiality not checked. A viability pilot in the target cell type, or a literature and dependency-dataset check, prevents the most expensive restart.

5. Redundancy unexamined. Paralogous expression analysis takes an afternoon and determines whether the design needs combinations.

The assessment produces a score; a build plan requires specific inputs:

• • Target gene and transcript, with the exon or region you intend to disrupt
• • Cell type and, where relevant, the differentiation protocol
• • The claim the model must support, in one sentence
• • Which constraints scored lowest
• • Timeline and documentation requirement
• • Any existing guides, delivery experience, or pilot data

With those, a modality recommendation and a validation package can be produced without further discovery.

It does not predict editing efficiency at your locus, and it is not a quote. It also does not capture biology: a well-scored project can still return a null if the pathway is buffered, and a poorly-scored one can succeed with the right modality.

What it does is make the constraints explicit before they become schedule.

"My score is low, but the gene is important. Should we drop it?"No. A low score means the current design is risky, not that the question is wrong. The usual fix is a modality change — inducible knockdown instead of knockout, or a pooled approach instead of clones.

"We scored well but have no protein blot capability."Then question 6 was over-scored. Protein-level confirmation is not optional for a null claim; if you cannot do it in-house, plan for it in the scope.

"Does a high score mean the knockout will work at my locus?"No. Editing efficiency is locus-specific. The score covers constraints that are visible before the experiment; it does not predict chromatin accessibility or guide activity at your site.

"We need the line in six weeks."Then the answer is usually an acute perturbation, not a clonal line. A knockout campaign with cloning, expansion and validation rarely fits six weeks in any cell type.

"Can the result replace a pilot experiment?"No. It tells you which pilot to run first, which is often the more valuable outcome.

The interactive version asks the ten questions, weights your answers, and returns a score, a recommended modality, and the gaps to close first. It runs in the browser with no data collected.

If you would rather have the plan than the score: send the locus, the cell type and your lowest-scoring constraints, and we will return a recommended modality, a validation package and a timeline. Contact EDITGENE to request a project consultation or quote.

The assessment encodes common failure modes in regulatory and translational knockout work. It is a planning aid, not a prediction of outcome, and it does not replace cell-type-specific pilot data.

Editing feasibility depends on locus, chromatin state, cell type and delivery method; any project plan should be conditioned on a pilot edit at the intended locus.

• • Doench JG. Am I ready for CRISPR? A user's guide to genetic screens. Nature Reviews Genetics. 2018;19:67–80.
• • Sentmanat MF, et al. A survey of validation strategies for CRISPR-Cas9 editing. Scientific Reports. 2018;8:888.
• • Ben-David U, et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018;560:325–330.